| VIEW POINT
|Year : 2010 | Volume
| Issue : 3 | Page : 226-228
Clinically effective CK-MB reporting: How to do it?
S Vivekanandan1, R Swaminathan2
1 Department of Clinical Biochemistry, Global Hospitals & Health City, Chennai, India
2 Department of Chemical Pathology, Guy's & St. Thomas Hospitals NHS Trust, London SE1 7EH, United Kingdom
The clinical utility of measuring the Muscle Brain (MB) isoenzyme of creatine kinase (CK) in the diagnosis of myocardial injury is well established. CK/CK-MB measurement in combination or CK-MB alone is widely used and reporting the results of CK-MB in absolute unit is the common current practice. CK-MB is widely measured by "Immunoinhibition" in India, which gives falsely elevated CK-MB results in the following circumstances: Central nervous system damage, childbirth, macro CK-immunoglobulin complex, in patients with carcinoma of various organs, such as prostate carcinoma and other adenocarcinomas. But, reporting %CK-MB rather than the absolute CK-MB results assists in detection of macroCK (or CK variants), associated proliferative and autoimmune pathologies and their prognosis.
Department of Clinical Biochemistry, Global Hospitals & Health City, Chennai
Source of Support: None, Conflict of Interest: None
[FULL TEXT] [PDF]*